Neuphoria Therapeutics (NEUP) Receivables (2020 - 2026)
Neuphoria Therapeutics (NEUP) reported Receivables of $2.4 million for Q1 2026, up 8675.58% year-over-year from $27500.0 in Q1 2025, and up 50.99% on a QoQ basis from $1.6 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 7 years of Receivables data on file, last reported at $2.4 million in Q1 2026.
- Quarterly Receivables rose 8675.58% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 8675.58% YoY) and the FY2025 annual result came in at $11948.0, down 94.64% from the prior year.
- Receivables climbed to $2.4 million in Q1 2026 per NEUP's latest filing, from $1.6 million in the prior quarter.
- Across five years, Receivables topped out at $4.9 million in Q2 2022 and bottomed at $3516.0 in Q3 2025.
- The 5-year median for Receivables is $127083.5 (2024), against an average of $943184.3.
- The widest annual swing landed in 2023, when Receivables plunged 99.79%; it then jumped 8675.58% in 2026.
- Tracing NEUP's Receivables over 5 years: stood at $4.9 million in 2022, then sank by 99.79% to $10429.1 in 2023, then jumped by 260.36% to $37582.0 in 2024, then soared by 4152.78% to $1.6 million in 2025, then surged by 50.99% to $2.4 million in 2026.
- Per Business Quant, the three latest NEUP Receivables figures stand at $2.4 million (Q1 2026), $1.6 million (Q4 2025), and $3516.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 2.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.41 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 3,516.00 |
| Jun 30, 2025 | 12,185.00 |
| Mar 31, 2025 | 27,500.00 |
| Dec 31, 2024 | 37,582.00 |
| Sep 30, 2024 | 117,236.00 |
| Jun 30, 2024 | 223,038.00 |
| Jun 30, 2023 | 429,272.54 |
| Jun 30, 2022 | 4.89 Mn |
| Jun 30, 2021 | 1.02 Mn |
| Jun 30, 2020 | 1.19 Mn |